Edesa Biotech, Inc.
EDSA · Pharmaceutical Preparations · 8.9M shares · +47%/yr ↑ shares · EDGAR filings ↗
Reference price $6.60 · est. market cap ~$59M — last insider purchase, 2026-03-10 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — dermatology/inflammation clinical, well-funded.
Strengths
- Liquidity — current ratio 10.7 (81st)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Going concernAccordingly, management has concluded that substantial doubt exists about our ability to continue as a going concern
- Exec changeRecent 8-K item 5.02 8-K ↗
- Insider buyingInsider buying — 9 open-market buy(s) by 2 insider(s) (cluster of 2 insiders, ~$233,054, last 6mo) Form 4 ↗
- Notable holderHeld by 1 notable fund(s): STATE STREET CORP (as of 2026-03-31)
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-57.7%
Return on assets
-53.1%
Current ratio
10.7×
EBITDA
-$8M
Tangible book value
$10M
Cash & investments
$11M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-16 | Nijhawan Pardeep | Grant | 154K | $5.21 |
| 2026-06-01 | Nijhawan Pardeep | Grant | 1.7K | — |
| 2026-05-27 | Marshall Patrick | Grant | 19K | — |
| 2026-05-27 | MacDonald Sean Arthur | Grant | 19K | — |
| 2026-05-27 | Chypyha Joan | Grant | 19K | — |
| 2026-05-27 | Weiler Peter J. | Grant | 65K | — |
| 2026-05-27 | Brooks Michael J | Grant | 65K | — |
| 2026-05-27 | Sistilli Carlo | Grant | 19K | — |
| 2026-05-27 | Olson Charles V | Grant | 19K | — |
| 2026-05-27 | Nijhawan Pardeep | Grant | 97K | — |
| 2026-05-27 | Liu Da David | Grant | 19K | — |
| 2026-05-01 | Nijhawan Pardeep | Grant | 1.2K | — |
| 2026-04-01 | Nijhawan Pardeep | Grant | 2.6K | — |
| 2026-03-10 | Nijhawan Pardeep | Buy | 1.0K | $6.60 |
| 2026-03-05 | Nijhawan Pardeep | Buy | 10K | $3.90 |
| 2026-03-04 | Nijhawan Pardeep | Buy | 10K | $4.26 |
| 2026-03-03 | Nijhawan Pardeep | Buy | 10K | $3.63 |
| 2026-03-02 | Nijhawan Pardeep | Grant | 10K | — |
| 2026-03-02 | Nijhawan Pardeep | Buy | 2.0K | $2.00 |
| 2026-03-02 | Nijhawan Pardeep | Buy | 1.0K | $2.28 |
| 2026-02-27 | Nijhawan Pardeep | Buy | 30K | $2.22 |
| 2026-02-26 | Brooks Michael J | Buy | 2.0K | $1.57 |
| 2026-02-26 | Nijhawan Pardeep | Buy | 21K | $1.58 |
| 2026-02-19 | Nijhawan Pardeep | Grant | 82K | — |
| 2026-02-02 | Nijhawan Pardeep | Grant | 11K | — |
| 2026-01-05 | Nijhawan Pardeep | Grant | 10K | — |
| 2025-12-01 | Nijhawan Pardeep | Grant | 8.8K | — |
| 2025-11-03 | Nijhawan Pardeep | Grant | 7.0K | — |
| 2025-10-02 | Nijhawan Pardeep | Grant | 5.9K | — |
| 2025-09-11 | Nijhawan Pardeep | Grant | 6.0K | — |
| 2025-08-01 | Nijhawan Pardeep | Grant | 6.8K | — |
| 2025-07-02 | Nijhawan Pardeep | Grant | 7.2K | — |
| 2025-06-02 | Nijhawan Pardeep | Grant | 7.6K | — |
| 2025-05-29 | Marshall Patrick | Grant | 11K | — |
| 2025-05-29 | Olson Charles V | Grant | 11K | — |
| 2025-05-29 | Sistilli Carlo | Grant | 20K | — |
| 2025-05-29 | Nijhawan Pardeep | Grant | 263K | — |
| 2025-05-29 | Weiler Peter J. | Grant | 65K | — |
| 2025-05-29 | MacDonald Sean Arthur | Grant | 20K | — |
| 2025-05-29 | Chypyha Joan | Grant | 11K | — |
| 2025-05-29 | Brooks Michael J | Grant | 207K | — |
| 2025-05-29 | Liu Da David | Grant | 5.5K | — |
| 2025-05-02 | Nijhawan Pardeep | Grant | 6.4K | — |
| 2025-04-01 | Nijhawan Pardeep | Grant | 5.8K | — |
| 2025-03-03 | Nijhawan Pardeep | Grant | 6.3K | — |
| 2025-02-12 | Sistilli Carlo | Grant | 10K | $1.92 |
| 2025-02-12 | Marshall Patrick | Grant | 42K | $1.92 |
| 2025-02-03 | Nijhawan Pardeep | Grant | 8.3K | — |
| 2025-01-06 | Nijhawan Pardeep | Grant | 8.5K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04401475 ↗ | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 COVID-19, ARDS | PHASE2/PHASE3 | Suspended | 2024-12-01 |
| NCT03680131 ↗ | Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis Allergic Contact Dermatitis | PHASE2 | Completed | 2022-09-21 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-11 | Material agreement3.02Reg FDExhibits | filing ↗ |
| 2026-06-05 | Other | filing ↗ |
| 2026-05-29 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-15 | Exec/director change | filing ↗ |
| 2026-05-14 | ResultsExhibits | filing ↗ |
| 2026-02-24 | Other | filing ↗ |
| 2026-02-13 | ResultsExhibits | filing ↗ |
| 2025-12-12 | OtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-11 | 2026-06-10 | 0001171843-26-004053 ↗ |
| 8-K | 2026-06-05 | 2026-06-05 | 0001171843-26-003931 ↗ |
| 8-K | 2026-05-29 | 2026-05-27 | 0001171843-26-003793 ↗ |
| 8-K | 2026-05-15 | 2026-05-13 | 0001171843-26-003459 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001171843-26-003433 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001171843-26-003429 ↗ |
| 8-K | 2026-02-24 | 2026-02-24 | 0001171843-26-001046 ↗ |
| 8-K | 2026-02-13 | 2026-02-13 | 0001171843-26-000810 ↗ |
| 10-Q | 2026-02-13 | 2025-12-31 | 0001171843-26-000812 ↗ |
| 8-K | 2025-12-12 | 2025-12-12 | 0001171843-25-007913 ↗ |
| 10-K | 2025-12-12 | 2025-09-30 | 0001171843-25-007914 ↗ |
| 8-K | 2025-12-12 | 2025-12-12 | 0001171843-25-007918 ↗ |